Overview

  • Product nameAnti-SQSTM1 / p62 antibody
    See all SQSTM1 / p62 primary antibodies
  • Description
    Sheep polyclonal to SQSTM1 / p62
  • Specificityab31545 recognises SQSTM1/p62 in normal and diseased human brain.
  • Tested applicationsIHC-P, IHC-Fr, WBmore details
  • Species reactivity
    Reacts with: Human
  • Immunogen

    Synthetic peptide from part of human Ubiquitin Interactive Motif (UIM) derived from p62 protein, also known as SQSTM1. Amino acid sequence: PPEADPRLIE SLSQMLSMGF SDEGGWLTRL LQTKNYDIGA

  • Positive control
    • Human brain homogenate
  • General notes


    In western blot the antibody recognizes 4 major bands of 130, 62, 45 and 22 kDa in human brain homogenate. The antibody may also recognize some proteins containing SQSTM1 domains from other species as 80, 62 and 47 kDa proteins are identified in rat sympathetic ganglia. Preincubation of the antibody with the immunizing peptide abolishes all reactivity in both human brain homogenate and rat sympathitic ganglia.

Properties

Applications

Our Abpromise guarantee covers the use of ab31545 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
IHC-P Use at an assay dependent dilution.
IHC-Fr 1/500 - 1/2000.
WB Use at an assay dependent dilution. Detects a band of approximately 47, 50 kDa (predicted molecular weight: 47 kDa).

Target

  • FunctionAdapter protein which binds ubiquitin and may regulate the activation of NFKB1 by TNF-alpha, nerve growth factor (NGF) and interleukin-1. May play a role in titin/TTN downstream signaling in muscle cells. May regulate signaling cascades through ubiquitination. Adapter that mediates the interaction between TRAF6 and CYLD (By similarity). May be involved in cell differentiation, apoptosis, immune response and regulation of K(+) channels.
  • Tissue specificityUbiquitously expressed.
  • Involvement in diseaseDefects in SQSTM1 are a cause of Paget disease of bone (PDB) [MIM:602080]. PDB is a metabolic bone disease affecting the axial skeleton and characterized by focal areas of increased and disorganized bone turn-over due to activated osteoclasts. Manifestations of the disease include bone pain, deformity, pathological fractures, deafness, neurological complications and increased risk of osteosarcoma. PDB is a chronic disease affecting 2 to 3% of the population above the age of 40 years.
  • Sequence similaritiesContains 1 OPR domain.
    Contains 1 UBA domain.
    Contains 1 ZZ-type zinc finger.
  • DomainThe UBA domain binds specifically 'Lys-63'-linked polyubiquitin chains of polyubiquitinated substrates. Mediates the interaction with TRIM55.
    The OPR domain mediates homooligomerization and interactions with PRKCZ, PRKCI, MAP2K5 and NBR1.
    The ZZ-type zinc finger mediates the interaction with RIPK1.
  • Post-translational
    modifications
    Phosphorylated. May be phosphorylated by PRKCZ (By similarity). Phosphorylated in vitro by TTN.
  • Cellular localizationCytoplasm. Late endosome. Nucleus. Sarcomere (By similarity). In cardiac muscles localizes to the sarcomeric band (By similarity). Localizes to late endosomes. May also localize to the nucleus. Accumulates in neurofibrillary tangles and in Lewy bodies of neurons from individuals with Alzheimer and Parkinson disease respectively. Enriched in Rosenthal fibers of pilocytic astrocytoma. In liver cells, accumulates in Mallory bodies associated with alcoholic hepatitis, Wilson disease, indian childhood cirrhosis and in hyaline bodies associated with hepatocellular carcinoma.
  • Information by UniProt
  • Database links
  • Alternative names
    • A170 antibody
    • EBI 3 associated protein of 60 kDa antibody
    • EBI 3 associated protein p60 antibody
    • EBI3 associated protein of 60 kDa antibody
    • EBI3 associated protein p60 antibody
    • EBI3-associated protein of 60 kDa antibody
    • EBIAP antibody
    • MGC127197 antibody
    • ORCA antibody
    • OSF-6 antibody
    • Osi antibody
    • OSIL antibody
    • Oxidative stress induced like antibody
    • p60 antibody
    • p62 antibody
    • p62B antibody
    • Paget disease of bone 3 antibody
    • PDB 3 antibody
    • PDB3 antibody
    • Phosphotyrosine independent ligand for the Lck SH2 domain of 62 kDa antibody
    • Phosphotyrosine independent ligand for the Lck SH2 domain p62 antibody
    • Phosphotyrosine-independent ligand for the Lck SH2 domain of 62 kDa antibody
    • PKC-zeta-interacting protein antibody
    • Protein kinase C-zeta-interacting protein antibody
    • Sequestosome 1 antibody
    • Sequestosome-1 antibody
    • SQSTM 1 antibody
    • SQSTM_HUMAN antibody
    • Sqstm1 antibody
    • STAP antibody
    • STONE14 antibody
    • Ubiquitin binding protein p62 antibody
    • Ubiquitin-binding protein p62 antibody
    • ZIP 3 antibody
    • ZIP antibody
    • ZIP3 antibody
    see all

Anti-SQSTM1 / p62 antibody images

  • All lanes : Anti-SQSTM1 / p62 antibody (ab31545) at 1/500 dilution

    Lane 1 : A549 (Human lung adenocarcinoma epithelial cell line) Whole Cell Lysate
    Lane 2 : MCF7 (Human breast adenocarcinoma cell line) Whole Cell Lysate
    Lane 3 : HepG2 (Human hepatocellular liver carcinoma cell line) Whole Cell Lysate

    Lysates/proteins at 10 µg per lane.

    Secondary
    Rabbit polyclonal Secondary Antibody to Sheep IgG - H&L (HRP) at 1/3000 dilution
    developed using the ECL technique

    Performed under reducing conditions.

    Predicted band size : 47 kDa
    Observed band size : 47 + 50 kDa (why is the actual band size different from the predicted?)


    Exposure time : 30 seconds
  • ab31545 staining SQSTM1 / p62 in murine spinal cord sections by Immunohistochemistry (Frozen sections).
    Tissue was fixed in 4% paraformaldehyde, blocked with 10% goat serum for 2 hours at 25°C and then incubated with ab31545 at a 1/500 dilution for 18 hours at 4°C. The secondary used was an Alexa-Fluor 594 conjugated donkey anti-sheep (H+L) polyclonal used at a 1/1000 dilution.

    See Abreview

References for Anti-SQSTM1 / p62 antibody (ab31545)

This product has been referenced in:
  • Puustinen P  et al. CIP2A oncoprotein controls cell growth and autophagy through mTORC1 activation. J Cell Biol 204:713-27 (2014). Human . Read more (PubMed: 24590173) »
  • Vanhorebeek I  et al. Insufficient activation of autophagy allows cellular damage to accumulate in critically ill patients. J Clin Endocrinol Metab 96:E633-45 (2011). WB ; Human . Read more (PubMed: 21270330) »

See all 3 Publications for this product

Product Wall

Application Immunohistochemistry (Frozen sections)
Sample Mouse Tissue sections (spinal cord)
Specification spinal cord
Fixative Paraformaldehyde
Permeabilization No
Blocking step Serum as blocking agent for 2 hour(s) and 0 minute(s) · Concentration: 10% · Temperature: 25°C
Username

Dr. Teresa Muñoz-Galdeano

Verified customer

Submitted Feb 04 2012

Thank you for contacting us. Unfortunately, we don’t have specific data regarding the reactivity of this antibody in Drosophila. It has only been tested in mammalian species. Could you please specify the source where you found the reference to the reac...

Read More
Abcam has not validated the combination of species/application used in this Abreview.
Application Western blot
Sample Fruit fly (Drosophila melanogaster) Cell lysate - whole cell (Kc cells)
Loading amount 1e+006 cells
Specification Kc cells
Treatment RNAi against indicated gene for three days
Gel Running Conditions Reduced Denaturing (8% Gel)
Blocking step Milk as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 5% · Temperature: 25°C
Username

Abcam user community

Verified customer

Submitted Jul 23 2010

Thank you for your enquiry. The synthetic peptide used to raise ab31545 was derived from part of human Ubiquitin Interactive Motif (UIM) derived from p62 protein, also known as SQSTM1. The amino acid sequence is as follows: PPEADPRLIE SLSQMLSMGF SD...

Read More

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"